Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST

被引：0

作者：

Inga-Marie Schaefer

Matthew L. Hemming

Meijun Z. Lundberg

Matthew P. Serrata

Isabel Goldaracena

Ninning Liu

Peng Yin

Joao A. Paulo

Steven P. Gygi

Suzanne George

Jeffrey A. Morgan

Monica M. Bertagnolli

Ewa T. Sicinska

Chen Chu

Shanshan Zheng

Adrian Mariño-Enríquez

Jason L. Hornick

Chandrajit P. Raut

Wen-Bin Ou

George D. Demetri

Sinem K. Saka

Jonathan A. Fletcher

机构：

[1] Harvard Medical School,Department of Pathology, Brigham and Women’s Hospital

[2] Dana-Farber Cancer Institute and Harvard Medical School,Department of Medical Oncology

[3] Dana-Farber Cancer Institute and Brigham and Women’s Hospital,Sarcoma Center

[4] Harvard University,Wyss Institute for Biologically Inspired Engineering

[5] Harvard Medical School,Department of Cell Biology

[6] Brigham and Women’s Hospital,Department of Surgery

[7] Harvard Medical School,Department of Pathology

[8] Dana-Farber Cancer Institute,Department of Cancer Biology

[9] Harvard Medical School,Department of Genetics

[10] Dana-Farber Cancer Institute,Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, College of Life Sciences and Medicine

[11] Blavatnik Institute,Ludwig Center at Harvard

[12] Harvard Medical School,European Molecular Biology Laboratory (EMBL)

[13] Zhejiang Sci-Tech University,undefined

[14] Harvard Medical School,undefined

[15] Genome Biology Unit,undefined

来源：

British Journal of Cancer | 2022年 / 127卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：2072 / 2085

页数：13

共 50 条

[21] MCL PATIENTS RESPOND TO CDK4/6 INHIBITION
不详
CANCER DISCOVERY, 2012, 2 (04) : 300 - 300
[22] The Role of CDK4/6 Inhibition in Breast Cancer
Murphy, Conleth G.
Dickler, Maura N.
ONCOLOGIST, 2015, 20 (05): : 483 - U49
[23] CDK4/6 inhibition in luminal breast cancer
Gampenrieder S.P.
Rinnerthaler G.
Greil R.
memo - Magazine of European Medical Oncology, 2016, 9 (2) : 76 - 81
[24] CDK4 amplification reduces sensitivity to CDK4/6 inhibition in fusion-positive rhabdomyosarcoma
Olanich, Mary E.
Sun, Wenyue
Hewitt, Stephen M.
Abdullaev, Zied
Pack, Svetlana D.
Barr, Frederic G.
CANCER RESEARCH, 2015, 75
[25] CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Olanich, Mary E.
Sun, Wenyue
Hewitt, Stephen M.
Abdullaev, Zied
Pack, Svetlana D.
Barr, Frederic G.
CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4947 - 4959
[26] INHIBITION STUDIES OF TERPENE BASED NATURAL PRODUCTS WITH CYCLIN-DEPENDENT KINASE 4 (CDK4 MIMIC CDK2)
Ganatra, Sunil H.
Suchak, Amita S.
INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2012, 3 (09): : 3196 - 3203
[27] Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft
Raub, Thomas J.
Wishart, Graham N.
Kulanthaivel, Palaniappan
Staton, Brian A.
Ajamie, Rose T.
Sawada, Geri A.
Gelbert, Lawrence M.
Shannon, Harlan E.
Sanchez-Martinez, Concepcion
De Dios, Alfonso
DRUG METABOLISM AND DISPOSITION, 2015, 43 (09) : 1360 - 1371
[28] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Abeer J. Al-Qasem
Carla L. Alves
Sidse Ehmsen
Martina Tuttolomondo
Mikkel G. Terp
Lene E. Johansen
Henriette Vever
Luna V. A. Hoeg
Daniel Elias
Martin Bak
Henrik J. Ditzel
npj Precision Oncology, 6
[29] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
Al-Qasem, Abeer J.
Alves, Carla L.
Ehmsen, Sidse
Tuttolomondo, Martina
Terp, Mikkel G.
Johansen, Lene E.
Vever, Henriette
Hoeg, Luna V. A.
Elias, Daniel
Bak, Martin
Ditzel, Henrik J.
NPJ PRECISION ONCOLOGY, 2022, 6 (01)
[30] Lysosome inhibition overcomes resistance to CDK4/6 inhibition in PDA.
Silva, Dilru
Kinsey, Conan
McMahon, Martin
CANCER RESEARCH, 2021, 81 (22) : 22 - 23

← 1 2 3 4 5 →